Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS/MS

被引:1
作者
Wang, Ting [1 ]
Jin, Chengcheng [1 ]
Jiang, Wen [1 ]
Zhao, Tingting [2 ]
Xu, Yanmei [3 ]
Li, Hui [3 ]
机构
[1] Hebei Univ Sci & Technol, Coll Chem & Pharmaceut Engn, Shijiazhuang, Peoples R China
[2] Hebei Med Univ, Coll Pharm, Shijiazhuang 050000, Peoples R China
[3] Hebei Inst Drug & Med Device Inspect, Shijiazhuang, Peoples R China
关键词
Mammalian target of rapamycin inhibitors; UHPLC-MS/MS; QuEChERS; Human plasma; CYCLOSPORINE-A; EVEROLIMUS; TACROLIMUS; EXTRACTION; SIROLIMUS;
D O I
10.1016/j.jpba.2023.115652
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A fast and reliable QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method for pre-processing combined with Ultra - high performance liquid chromatography - tandem mass spectrometry (UHPLC-MS/MS) was established for the analysis of five mammalian rapamycin target protein (mTOR) inhibitors (vistusertib, AZD8055, pictilisib, everolimus, temsirolimus)in human plasma. Extraction was achieved by addition of acetonitrile to the sample followed by anhydrous magnesium sulfate and 30 mg C18 for salting out and purification, respectively. MTOR inhibitors were detected using selective response monitoring (SRM) under positive ion electrospray mode. Vistusertib, AZD8055 and pictilisib showed good linearity with a range of 1-80 ng/ml, Additionally, the concentration of everolimus and temsirolimus was 2.5-200 ng/ml and10-800 ng/ml, respectively. The linear correlation coefficient (R2) of each analysis was & GE; 0.9950. The limit of detection (LOD) and Limit of Quantitation (LOQ) were 0.015-0.75 ng/ml and 1-10 ng/ml, respectively. This method showed a high accuracy with high recovery rate and excellent stability. This method is fast, accurate and reliable, suitable for quantitative detection of mTOR inhibitors in human plasma.
引用
收藏
页数:10
相关论文
共 33 条
  • [1] LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing?s Syndrome
    Balakirouchenane, David
    Vasseur, Axelle
    Bonnet-Serrano, Fideline
    Choi, Minna
    Khoudour, Nihel
    Puszkiel, Alicja
    Groussin, Lionel
    Vidal, Michel
    Decleves, Xavier
    Bertherat, Jerome
    Blanchet, Benoit
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 228
  • [2] Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients
    Bodnar-Broniarczyk, Magdalena
    Warzyszynska, Karola
    Czerwinska, Katarzyna
    Marszalek, Dorota
    Dziewa, Natalia
    Kosieradzki, Maciej
    Pawinski, Tomasz
    [J]. PHARMACEUTICS, 2022, 14 (03)
  • [3] Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects
    Bouabdallah, Krimo
    Ribrag, Vincent
    Terriou, Louis
    Soria, Jean-Charles
    Delarue, Richard
    [J]. CURRENT OPINION IN ONCOLOGY, 2013, 25 : S1 - S12
  • [4] High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood
    Brignol, N
    McMahon, LM
    Luo, S
    Tse, FLS
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2001, 15 (12) : 898 - 907
  • [5] Optimization of QuEChERS extraction for detection and quantification of 20 antidepressants in postmortem blood samples by LC-MS/MS
    Campelo, Jacqueline de M.
    Rodrigues, Tais B.
    Costa, Jose L.
    Santos, Jandyson M.
    [J]. FORENSIC SCIENCE INTERNATIONAL, 2021, 319
  • [6] Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy
    Chen, Lichan
    Wei, Xiafei
    Gu, Dayong
    Xu, Yong
    Zhou, Hongzhong
    [J]. CANCER LETTERS, 2023, 555
  • [7] Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation
    Cholongitas, E.
    Antoniadis, N.
    Goulis, I.
    Theocharidou, E.
    Imvrios, G.
    Giouleme, O.
    Filis, D.
    Mouloudi, E.
    Akriviadis, E.
    Fouzas, I.
    [J]. TRANSPLANTATION PROCEEDINGS, 2019, 51 (02) : 450 - 453
  • [8] Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
    Deng, Shanshan
    Solinas, Antonio
    Calvisi, Diego F.
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] FDA, 2018, BIOAN METH VAL GUID
  • [10] A high-throughput LC-MS/MS method for the quantification of four immunosu- ppressants drugs in whole blood
    Gong, Zi-Shan
    Wu, Zhong-Hao
    Xu, Shu-Xin
    Han, Wen-Nian
    Jiang, Xiao-Mei
    Liu, Hai -Pei
    Yan-Li
    Wei-Hu
    Yan-Wang
    [J]. CLINICA CHIMICA ACTA, 2019, 498 : 21 - 26